{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:59:40Z","timestamp":1791464380743,"version":"4.3.4"},"reference-count":91,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T00:00:00Z","timestamp":1642636800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Intraepithelial mammary ductal neoplasia is a spectrum of disease that varies from atypical ductal hyperplasia (ADH), low-grade (LG), intermediate-grade (IG), to high-grade (HG) ductal carcinoma in situ (DCIS). While ADH has the lowest prognostic significance, HG-DCIS carries the highest risk. Due to widely used screening mammography, the number of intraepithelial mammary ductal neoplastic lesions has increased. The consequence of this practice is the increase in the number of patients who are overdiagnosed and, therefore, overtreated. The active surveillance (AS) trials are initiated to separate lesions that require active treatment from those that can be safely monitored and only be treated when they develop a change in the clinical\/radiologic characteristics. At the same time, the natural history of these lesions can be evaluated. This review aims to evaluate ADH\/DCIS as a spectrum of intraductal neoplastic disease (risk and histomorphology); examine the controversies of distinguishing ADH vs. DCIS and the grading of DCIS; review the upgrading for both ADH and DCIS with emphasis on the variation of methods of detection and the definitions of upgrading; and evaluate the impact of all these variables on the AS trials.<\/jats:p>","DOI":"10.3390\/cancers14030507","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T22:40:20Z","timestamp":1642718420000},"page":"507","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Preneoplastic Low-Risk Mammary Ductal Lesions (Atypical Ductal Hyperplasia and Ductal Carcinoma In Situ Spectrum): Current Status and Future Directions"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8112-6590","authenticated-orcid":false,"given":"Thaer","family":"Khoury","sequence":"first","affiliation":[{"name":"Department of Pathology, Roswell Park Cancer Institute, Elm & Carlton Streets, Buffalo, NY 14263, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/PAS.0b013e318161d1a5","article-title":"Morphologic and Molecular Evolutionary Pathways of Low Nuclear Grade Invasive Breast Cancers and Their Putative Precursor Lesions: Further Evidence to Support the Concept of Low Nuclear Grade Breast Neoplasia Family","volume":"32","author":"Powe","year":"2008","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1365-2559.2010.03568.x","article-title":"Breast cancer precursors revisited: Molecular features and progression pathways","volume":"57","author":"Geyer","year":"2010","journal-title":"Histopathology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1002\/cncr.29199","article-title":"Trends in breast biopsy pathology diagnoses among women undergoing mammography in the United States: A report from the Breast Cancer Surveillance Consortium","volume":"121","author":"Allison","year":"2015","journal-title":"Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/1097-0142(19850601)55:11<2698::AID-CNCR2820551127>3.0.CO;2-A","article-title":"Atypical hyperplastic lesions of the female breast. A long-term follow-up study","volume":"55","author":"Page","year":"1985","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/1097-0142(19900201)65:3<518::AID-CNCR2820650324>3.0.CO;2-O","article-title":"A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast","volume":"65","author":"Tavassoli","year":"1990","journal-title":"Cancer"},{"key":"ref_7","unstructured":"(2021, November 18). SEER Cancer Statistics (CSR) 1975\u20132016, Available online: https:\/\/seer.cancer.gov\/archive\/csr\/1975_2016\/."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s11864-012-0217-1","article-title":"Is DCIS breast cancer, and how do I treat it?","volume":"14","author":"Bijker","year":"2013","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1470-2045(10)70266-7","article-title":"Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: Long-term results from the UK\/ANZ DCIS trial","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2013.49.5077","article-title":"Breast-Conserving Treatment with or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome after a Recurrence, from the EORTC 10853 Randomized Phase III Trial","volume":"31","author":"Donker","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_11","first-page":"Cd000563","article-title":"Post-operative radiotherapy for ductal carcinoma in situ of the breast","volume":"11","author":"Goodwin","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0140-6736(99)05036-9","article-title":"Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial","volume":"353","author":"Fisher","year":"1999","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","article-title":"Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study","volume":"90","author":"Fisher","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1200\/JCO.19.02888","article-title":"De-Escalation of Locoregional Therapy in Low-Risk Disease for DCIS and Early-Stage Invasive Cancer","volume":"38","author":"Hwang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e026797","DOI":"10.1136\/bmjopen-2018-026797","article-title":"The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: A phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS)","volume":"9","author":"Hwang","year":"2019","journal-title":"BMJ Open"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.ejca.2015.07.017","article-title":"Addressing overtreatment of screen detected DCIS; the LORIS trial","volume":"51","author":"Francis","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.ejca.2015.05.008","article-title":"Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ\u2014The LORD study","volume":"51","author":"Elshof","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/jjco\/hyx059","article-title":"Current approach and future perspective for ductal carcinoma in situ of the breast","volume":"47","author":"Kanbayashi","year":"2017","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10549-007-9824-0","article-title":"Scoring system for predicting malignancy in patients diagnosed with atypical ductal hyperplasia at ultrasound-guided core needle biopsy","volume":"112","author":"Ko","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/his.12635","article-title":"Nomogram to predict the likelihood of upgrade of atypical ductal hyperplasia diagnosed on a core needle biopsy in mammographically detected lesions","volume":"67","author":"Khoury","year":"2015","journal-title":"Histopathology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/jso.20445","article-title":"Predictors of invasive disease in breast cancer when core biopsy demonstrates DCIS only","volume":"93","author":"Dillon","year":"2006","journal-title":"J. Surg. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1148\/radiol.11102368","article-title":"Ductal Carcinoma in Situ at Core-Needle Biopsy: Meta-Analysis of Underestimation and Predictors of Invasive Breast Cancer","volume":"260","author":"Brennan","year":"2011","journal-title":"Radiology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/ajcp\/aqaa276","article-title":"Significance of Removing Comedonecrosis as an Exclusion Criterion in Mammary Low-Risk Ductal Carcinoma In Situ Managed in an Active Surveillance Clinical Trial","volume":"156","author":"Zhan","year":"2021","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/s41379-019-0262-4","article-title":"Variability in diagnostic threshold for comedo necrosis among breast pathologists: Implications for patient eligibility for active surveillance trials of ductal carcinoma in situ","volume":"32","author":"Harrison","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0140-6736(03)13859-7","article-title":"Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: Randomised controlled trial","volume":"362","author":"Houghton","year":"2003","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/jnci\/djr027","article-title":"Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS","volume":"103","author":"Wapnir","year":"2011","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1056\/NEJMsr1407164","article-title":"Atypical hyperplasia of the breast--risk assessment and management options","volume":"372","author":"Hartmann","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/ans.13659","article-title":"Not all ductal carcinoma in situ is created equal: Can we avoid surgery for low-risk ductal carcinoma in situ?","volume":"86","author":"Lippey","year":"2016","journal-title":"ANZ J. Surg."},{"key":"ref_29","first-page":"5441","article-title":"Atypical Hyperplasia of the Breast: The Black Hole of Routine Breast Cancer Screening","volume":"32","author":"Picouleau","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2214\/AJR.08.1342","article-title":"Frequency and upgrade rates of atypical ductal hyperplasia diagnosed at stereotactic vacuum-assisted breast biopsy: 9-versus 11-gauge","volume":"192","author":"Eby","year":"2009","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/jnci\/90.11.864","article-title":"Diagnostic drift in the reporting of cancer incidence","volume":"90","author":"Bailar","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_32","first-page":"1053","article-title":"Benign breast changes and the risk for subsequent breast cancer: An update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists","volume":"122","author":"Fitzgibbons","year":"1998","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Amin, A., Winblad, O., Zupon, A., Fan, F., Tawfik, O., Wick, J., Hunt, S., Gatewood, J., Incardi, M., and Redick, M. (2021). Atypical ductal hyperplasia on percutaneous breast biopsy: Scoring system to identify the lowest risk for upgrade. Res. Sq.","DOI":"10.21203\/rs.3.rs-388478\/v1"},{"key":"ref_34","unstructured":"Board, E. (2019). Ductal Carcinoma in Situ. WHO Classification of Tumours\u2014Breast Tumours, IARC. [5th ed.]."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1016\/j.clbc.2019.08.002","article-title":"Ductal Carcinoma in Situ: A French National Survey. Analysis of 2125 Patients","volume":"20","author":"Cutuli","year":"2020","journal-title":"Clin. Breast Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1245\/s10434-007-9459-8","article-title":"Correlation of levels and patterns of genomic instability with histological grading of DCIS","volume":"14","author":"Ellsworth","year":"2007","journal-title":"Ann. Surg. Oncol."},{"key":"ref_37","unstructured":"Allison, K.H.C.L., Sanders, M.E., and Visscher, D.W. (2019). Atypical ductal hyperplasia. WHO Classification of Tumours\u2014Breast Tumours, IARC. [5th ed.]."},{"key":"ref_38","unstructured":"Stuart, J., and Schnitt, L.C.C. (2018). Intraductal proliferative lesions: Usual ductal hyperplasia, atypical ductal hyperplasia and ductal carcinoma in situ. Biopsy Interpretation of the Breast, Wolters Kluwer."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1148\/radiol.2019190748","article-title":"Upgrade Rate of Percutaneously Diagnosed Pure Atypical Ductal Hyperplasia: Systematic Review and Meta-Analysis of 6458 Lesions","volume":"294","author":"Schiaffino","year":"2020","journal-title":"Radiology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1148\/radiology.202.3.9051043","article-title":"Stereotactic breast biopsy of atypical ductal hyperplasia and ductal carcinoma in situ lesions: Improved accuracy with directional, vacuum-assisted biopsy","volume":"202","author":"Burbank","year":"1997","journal-title":"Radiology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12032-010-9494-3","article-title":"Experience in large-core needle biopsy in the diagnosis of 1431 breast lesions","volume":"28","author":"Wei","year":"2011","journal-title":"Med. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1746-1596-9-121","article-title":"Inter-observer variability between general pathologists and a specialist in breast pathology in the diagnosis of lobular neoplasia, columnar cell lesions, atypical ductal hyperplasia and ductal carcinoma in situ of the breast","volume":"9","author":"Gomes","year":"2014","journal-title":"Diagn. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1177\/1066896916662154","article-title":"Atypical Ductal Hyperplasia Bordering on Ductal Carcinoma In Situ","volume":"25","author":"Tozbikian","year":"2017","journal-title":"Int. J. Surg. Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"609841","DOI":"10.3389\/fonc.2020.609841","article-title":"Development and Validation of a Simple-to-Use Nomogram for Predicting the Upgrade of Atypical Ductal Hyperplasia on Core Needle Biopsy in Ultrasound-Detected Breast Lesions","volume":"10","author":"Huang","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/his.12811","article-title":"The risk of upgrade for atypical ductal hyperplasia detected on magnetic resonance imaging-guided biopsy: A study of 100 cases from four academic institutions","volume":"68","author":"Khoury","year":"2016","journal-title":"Histopathology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1148\/radiology.218.2.r01fe35497","article-title":"Stereotactic breast biopsy of nonpalpable lesions: Determinants of ductal carcinoma in situ underestimation rates","volume":"218","author":"Jackman","year":"2001","journal-title":"Radiology"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Nicosia, L., Di Giulio, G., Bozzini, A.C., Fanizza, M., Ballati, F., Rotili, A., Lazzeroni, M., Latronico, A., Abbate, F., and Renne, G. (2021). Active Surveillance in the Management of Ductal Carcinoma in Situ: The Radiologist\u2019s Point of View. Cancers, 13.","DOI":"10.3390\/cancers13040868"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/ajcp\/aqz143","article-title":"Atypical Ductal Hyperplasia and Those Bordering on Ductal Carcinoma In Situ Should Be Included in the Active Surveillance Clinical Trials","volume":"153","author":"Khoury","year":"2019","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/modpathol.2017.114","article-title":"Active surveillance of women diagnosed with atypical ductal hyperplasia on core needle biopsy may spare many women potentially unnecessary surgery, but at the risk of undertreatment for a minority: 10-year surgical outcomes of 114 consecutive cases from a single center","volume":"31","author":"Farshid","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1245\/s10434-017-6018-9","article-title":"Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials","volume":"24","author":"Grimm","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.ejso.2013.09.028","article-title":"Concordance between vacuum assisted biopsy and postoperative histology: Implications for the proposed Low Risk DCIS Trial (LORIS)","volume":"39","author":"Soumian","year":"2013","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1245\/s10434-016-5268-2","article-title":"Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?","volume":"23","author":"Pilewskie","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1245\/s10434-017-5927-y","article-title":"A Validated Nomogram to Predict Upstaging of Ductal Carcinoma in Situ to Invasive Disease","volume":"24","author":"Jakub","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"712","DOI":"10.2214\/AJR.17.19244","article-title":"Patient Selection for Ductal Carcinoma In Situ Observation Trials: Are the Lesions Truly Low Risk?","volume":"211","author":"Patel","year":"2018","journal-title":"AJR Am. J. Roentgenol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"4459","DOI":"10.1245\/s10434-020-08576-6","article-title":"Do Eligibility Criteria for Ductal Carcinoma In Situ (DCIS) Active Surveillance Trials Identify Patients at Low Risk for Upgrade to Invasive Carcinoma?","volume":"27","author":"Oseni","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/his.14539","article-title":"Touching tumour-infiltrating lymphocytes in low-risk ductal carcinoma in situ (DCIS) correlate with upgrading to high-grade DCIS","volume":"80","author":"Khoury","year":"2021","journal-title":"Histopathology"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/jjco\/hyab082","article-title":"Surgical upstaging rates in patients meeting the eligibility for active surveillance trials","volume":"51","author":"Iwamoto","year":"2021","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamasurg.2017.2181","article-title":"Factors Associated With Underestimation of Invasive Cancer in Patients With Ductal Carcinoma In Situ: Precautions for Active Surveillance","volume":"152","author":"Bonev","year":"2017","journal-title":"JAMA Surg."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/ajcp\/aqaa077","article-title":"Interobserver Variability in Ductal Carcinoma In Situ of the Breast","volume":"154","author":"Duhoux","year":"2020","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41379-019-0367-9","article-title":"Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: The DCISion study","volume":"33","author":"Dano","year":"2020","journal-title":"Mod. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0046-8177(99)90002-3","article-title":"Interobserver reproducibility of the Lagios nuclear grading system for ductal carcinoma in situ","volume":"30","author":"Sneige","year":"1999","journal-title":"Hum. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10549-018-05082-y","article-title":"Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: A nationwide study of 4901 patients in The Netherlands","volume":"174","author":"Willems","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.5858\/arpa.2017-0268-OA","article-title":"Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery","volume":"142","author":"Podoll","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"7388","DOI":"10.1158\/1078-0432.CCR-19-0463","article-title":"Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer","volume":"25","author":"He","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1002\/cncr.32878","article-title":"Adjuvant chemotherapy for small, lymph node\u2013negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature","volume":"126","author":"An","year":"2020","journal-title":"Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s12253-019-00760-8","article-title":"Grading Ductal Carcinoma In Situ (DCIS) of the Breast\u2014What\u2019s Wrong with It?","volume":"26","author":"Cserni","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"The Consensus Conference Committee (1997). Consensus Conference on the classification of ductal carcinoma in situ. Cancer, 80, 1798\u20131802.","DOI":"10.1002\/(SICI)1097-0142(19971101)80:9<1798::AID-CNCR15>3.0.CO;2-0"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0039-6109(16)45185-6","article-title":"Duct carcinoma in situ. Pathology and treatment","volume":"70","author":"Lagios","year":"1990","journal-title":"Surg. Clin. N. Am."},{"key":"ref_69","unstructured":"College of American Pathologists (2021, December 01). Protocol for the Examination of Resection Specimens from Patients with Ductal Carcinoma In Situ (DCIS) of the Breast. Available online: https:\/\/documents.cap.org\/protocols\/Breast.DCIS_4.4.0.0.REL_CAPCP.pdf."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/cncr.20979","article-title":"Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: Results from the Nurses\u2019 Health Study","volume":"103","author":"Collins","year":"2005","journal-title":"Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1002\/cncr.21069","article-title":"The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up","volume":"103","author":"Sanders","year":"2005","journal-title":"Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ejso.2017.12.007","article-title":"Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ","volume":"44","author":"Maxwell","year":"2018","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1093\/jnci\/djy220","article-title":"Cancer Outcomes in DCIS Patients Without Locoregional Treatment","volume":"111","author":"Ryser","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13058-020-01287-6","article-title":"Modeling the natural history of ductal carcinoma in situ based on population data","volume":"22","author":"Chootipongchaivat","year":"2020","journal-title":"Breast Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1200\/JCO.2009.26.8847","article-title":"Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal carcinoma in situ","volume":"28","author":"Rudloff","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10549-015-3464-6","article-title":"A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone","volume":"152","author":"Rakovitch","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10549-018-4693-2","article-title":"Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: A combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies","volume":"169","author":"Rakovitch","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/jncimonographs\/lgq040","article-title":"Choosing treatment for patients with ductal carcinoma in situ: Fine tuning the University of Southern California\/Van Nuys Prognostic Index","volume":"2010","author":"Silverstein","year":"2010","journal-title":"J. Natl. Cancer Inst. Monogr."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.ajpath.2018.12.003","article-title":"Molecular Evaluation of Breast Ductal Carcinoma in Situ with Oncotype DX DCIS","volume":"189","author":"Hanna","year":"2019","journal-title":"Am. J. Pathol."},{"key":"ref_80","unstructured":"(2021, December 01). Breast Cancer Screening and Diagnosis. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast-screening.pdf."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.amjsurg.2013.10.029","article-title":"Management of patients diagnosed with atypical ductal hyperplasia by vacuum-assisted core biopsy: A prospective assessment of the guidelines used at our institution","volume":"208","author":"Caplain","year":"2014","journal-title":"Am. J. Surg."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/1097-0142(20010701)92:1<172::AID-CNCR1306>3.0.CO;2-K","article-title":"Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma","volume":"92","author":"Huang","year":"2001","journal-title":"Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.1200\/JCO.2007.12.1665","article-title":"Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Safety analysis of BIG 1-98 trial","volume":"25","author":"Mouridsen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_84","first-page":"209","article-title":"Heterogeneity Between Ducts of the Same Nuclear Grade Involved by Duct Carcinoma In Situ (DCIS) of the Breast","volume":"9","author":"Miller","year":"2010","journal-title":"Cancer Inf."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.molonc.2013.07.005","article-title":"Progression from ductal carcinoma in situ to invasive breast cancer: Revisited","volume":"7","author":"Cowell","year":"2013","journal-title":"Mol. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1097\/00000478-199212000-00001","article-title":"Interobserver reproducibility in the diagnosis of ductal proliferative breast lesions using standardized criteria","volume":"16","author":"Schnitt","year":"1992","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"649","DOI":"10.7326\/M15-0964","article-title":"Variability in Pathologists\u2019 Interpretations of Individual Breast Biopsy Slides: A Population Perspective","volume":"164","author":"Elmore","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jama.2015.1405","article-title":"Diagnostic concordance among pathologists interpreting breast biopsy specimens","volume":"313","author":"Elmore","year":"2015","journal-title":"JAMA"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1245\/s10434-016-5695-0","article-title":"Diagnostic Reproducibility: What Happens When the Same Pathologist Interprets the Same Breast Biopsy Specimen at Two Points in Time?","volume":"24","author":"Jackson","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1046\/j.1524-4741.2001.99124.x","article-title":"In situ duct carcinoma of the breast: Clinical and histopathologic factors and association with recurrent carcinoma","volume":"7","author":"Miller","year":"2001","journal-title":"Breast J."},{"key":"ref_91","unstructured":"Ellis, I.O.C.P., Hales, S., Lee, A.H.S., Pinder, S.E., Rakha, E., Al-Sam, S., Deb, R., Hanby, A., Liebmann, R., and Provenzano, E. (2021, December 03). Pathology Reporting of Breast Disease in Surgical Excision Specimens Incorporating the Dataset for Histological Reporting of Breast Cancer. Available online: https:\/\/www.rcpath.org\/uploads\/assets\/7763be1c-d330-40e8-95d08f955752792a\/G148_BreastDataset-hires-Jun16.pdf."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/507\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:04:29Z","timestamp":1760133869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/3\/507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":91,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14030507"],"URL":"https:\/\/doi.org\/10.3390\/cancers14030507","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]}}}